Longevity Biomedical, Inc. Sample Contracts
FOURTH AMENDMENT AND SUPPLEMENT TO THE CONTRIBUTION AND EXCHANGE AGREEMENTContribution and Exchange Agreement • November 12th, 2025 • Longevity Biomedical, Inc.
This Fourth Amendment and Supplement to the Contribution and Exchange Agreement (this “Amendment”) is entered into as of August 8, 2024 (the “Amendment Date”) by and among Longevity Biomedical, Inc., a Delaware corporation (“Purchaser”), Cerevast Medical, Inc., a Delaware corporation (the “Company”), Andrew Leo, Louis J. Fox, Mark S. Humayun, Jennifer Fox Crisp, J. Andy Corley, Li Changan, Qian Xiaoming, William Brinton, Jr., Kirk Clothier, Eric Manegold, Bill Brinton, Sr., Debra Brinton, Julian McQueen, Denice Vezitinski, Travis Rothlisberger, Incline Silo A., LLC, a Nevada limited liability company, Haiyin Capital Investment Limited, a Chinese company limited by shares, Haiyin Equity Investment Fund LP, a Chinese limited partnership, Haiyin Equity Investment Fund II LP, a Chinese limited partnership, Haiyin Tech LP, a British Virgin Islands limited partnership, Hercules Bioventure, LP, a company established in the British Virgin Islands, and Network Victory Limited, a company establi
FOURTH AMENDMENT AND SUPPLEMENT TO THE CONTRIBUTION AND EXCHANGE AGREEMENTContribution and Exchange Agreement • November 12th, 2025 • Longevity Biomedical, Inc.
This Fourth Amendment and Supplement to the Contribution and Exchange Agreement (this “Amendment”) is entered into as of August 8, 2024 (the “Amendment Date”) by and among Longevity Biomedical, Inc., a Delaware corporation (“Purchaser”), Aegeria Soft Tissue, LLC, a Delaware limited liability company (the “Company”), Jennifer Elisseeff, Alessandro Ovi, Lee R. Marks, The Johns Hopkins University, Sestant SpA, an Italian company, Patrick Byrnes, Romano Prodi, Kofi Boahene, Andrew Pardoll, and Jim Forsell (each an “Owner” and together, the “Owners”), and Jennifer Elisseeff, as representative of the Owners (the “Owners’ Representative”, and together with the Purchaser, Company and the Owners, the “Parties”). Terms used but not otherwise defined in this Amendment shall have the meanings set forth in the C&E Agreement (as that term is defined below).
FIRST AMENDMENT TO ASSIGNMENT, ASSUMPTION AND NOTE CONVERSION AGREEMENTAssignment, Assumption and Note Conversion Agreement • November 12th, 2025 • Longevity Biomedical, Inc.
THIS FIRST AMENDMENT TO ASSIGNMENT, ASSUMPTION AND NOTE CONVERSION AGREEMENT (the “First Amendment”), effective as of September 12, 2024 (the “Amendment Date”), is among Longevity Biomedical, Inc., a Delaware corporation (the “Company”), FutureTech Partners LLC, a Delaware limited liability company (“Partners”), and FutureTech Capital LLC, a Delaware limited liability company (“Capital”).